Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals    VRTX

VERTEX PHARMACEUTICALS (VRTX)
Mes dernières consult.
Most popular
Report
Delayed Quote. Delayed  - 12/12 10:00:00 pm
140.91 USD   -0.54%
12/11 NASDAQ 100 MOVE : Orly, bmrn
12/11 VERTEX PHARMACE : Announces Positive Results from Open-Label Phase 3..
12/09 Tax-loss selling to pressure 2017's losers in December
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Nasdaq 100 Movers: ORLY, BMRN

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/11/2017 | 04:26pm CET

In early trading on Monday, shares of BioMarin Pharmaceutical (BMRN) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 8.3%. Year to date, BioMarin Pharmaceutical registers a 7.2% gain.

And the worst performing Nasdaq 100 component thus far on the day is O'Reilly Automotive (ORLY), trading down 1.2%. O'Reilly Automotive is lower by about 10.9% looking at the year to date performance.

Two other components making moves today are Vertex Pharmaceuticals (VRTX), trading down 1.1%, and Wynn Resorts (WYNN), trading up 3.2% on the day.

© BNK Invest, source Videos

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VERTEX PHARMACEUTICALS
12/11 NASDAQ 100 MOVERS : Orly, bmrn
12/11 VERTEX PHARMACEUTICALS : Announces Positive Results from Open-Label Phase 3 Stud..
12/09 Tax-loss selling to pressure 2017's losers in December
12/07 VERTEX PHARMACEUTICALS : Announces Positive Results from Open-Label Phase 3 Stud..
11/21 VERTEX PHARMACEUTICALS : Receives CHMP Positive Opinion for ORKAMBI® lumacaftor/..
11/20 S&P 500 MOVERS : Vrtx, dlph
11/16 VERTEX PHARMACEUTICALS : Announces Presentations of Data at North American Cysti..
11/15 Investor Expectations to Drive Momentum within Barracuda Networks, Abraxas Pe..
11/14 Concert Pharmaceuticals Reports Third Quarter 2017 Financial Results and Prov..
11/13 VERTEX PHARMACEUTICALS : Earnings Review and Free Research Report: Vertex’s Reve..
More news
News from SeekingAlpha
12/12 CRISPR Therapeutics and Vertex team up to advance and commercialize lead gene..
12/12 CUTTING EDGE GENE THERAPIES : Beta-Thalassemia Breakthroughs (Part I)
12/12 Proteostasis advances cystic fibrosis pipeline; shares ahead 59% premarket
12/11 Global Blood Therapeutics And Crispr - Which Firm Will Capture The Lucrative ..
12/08 STOCK EXCHANGE : Going Beyond Fundamentals, 3 Attractive Ideas
Financials ($)
Sales 2017 2 372 M
EBIT 2017 537 M
Net income 2017 256 M
Finance 2017 920 M
Yield 2017 -
P/E ratio 2017 151,27
P/E ratio 2018 79,57
EV / Sales 2017 14,7x
EV / Sales 2018 12,5x
Capitalization 35 831 M
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | VRTX | US92532F1003 | 4-Traders
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 183 $
Spread / Average Target 29%
EPS Revisions
Managers
NameTitle
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Ian F. Smith Chief Operating Officer & Executive Vice President
Thomas Graney Chief Financial Officer & Senior Vice President
Jeffrey A. Chodakewitz Chief Medical Officer & Executive Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS88.38%35 831
GILEAD SCIENCES1.55%99 094
REGENERON PHARMACEUTICALS1.78%40 969
GENMAB1.79%11 452
BLUEBIRD BIO INC172.12%9 249
EXELIXIS, INC.80.42%7 816